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Summary 
The T cell surface molecule CD28 can provide costimulatory signals that permit the full activation 
of T  cells.  Here we demonstrate that stimulation of CD28,  either by B7,  its natural ligand, 
or by the anti-CD28  monoclonal antibody 9.3,  induces an  association between CD28  and 
phosphatidylinositol 3-kinase (PI3-K) in Jurkat T cells, raising the possibility that an interaction 
with PI3-K contributes to CD28-mediated signaling. To examine the mechanism of the association, 
we synthesized tyrosine-phosphorylated oligopeptides corresponding to each of the four tyrosines 
in the CD28  cytoplasmic domain.  When added to lysates  of B7-stimulated Jurkat cells,  the 
oligopeptide corresponding to Tyr 173 inhibits the coimmunoprecipitation of PI3-K with CD28; 
the other oligopeptides have no effect. Tyr 173 is contained within the sequence YMNM,  a 
motif that is also found in the platelet-derived growth factor receptor and that, when phosphorylated, 
forms a high af~nity binding site for the p85 subunit of PI3-K. These observations suggest that 
phosphorylation of Tyr 173 may mediate the interaction between CD28 and PI3-K. However, 
because CD28 is not known to be phosphorylated, it remains possible that CD28 interacts with 
PI3-K through a mechanism independent of tyrosine phosphorylation. 
T  ceU activation in response to antigen depends upon stimu- 
lation of the TCR and upon signals delivered through 
accessory T cell molecules (1, 2). In the absence of the proper 
costimulus, TCR signaling can induce a long-lasting anergic 
state in which appropriate presentation of antigen fails to elicit 
IL-2 production (3). Recent studies indicate that CD28 func- 
tions  as a T  cell accessory molecule capable  of delivering 
costimulatory signals. CD28 binds B7 (also designated BB1), 
a molecule expressed by activated B cells, macrophages, and 
other APCs (4-6). Stimulation of CD28 prevents anergy in- 
duction in T  cell clones (7).  Conversely, disruption of the 
interaction between CD28 and B7 induces alloantigen-specific 
hyporesponsiveness in T  cells in vitro,  and blockade of B7 
in vitro prolongs the survival of xenografts and allografts 
(8-10). Perturbation of CD28 augments TCR-induced pro- 
duction of lymphokines (2). The CD28 signals appear both 
to influence the transcription of the IL-2 gene and to en- 
hance the stability of IL-2 transcripts (11, 12). Under certain 
conditions, CD28 delivers activation signals to T cells in the 
absence of TCR ligation.  In the presence of PMA, for ex- 
ample, the addition of soluble anti-CD28 mAbs stimulates 
T  cell proliferation (13). 
The mechanism of transmembrane signaling by CD28 re- 
mains uncertain. When T  cells have been pretreated with 
either a TCR mAb or with PMA, stimulation of CD28 leads 
to the appearance of tyrosine-phosphorylated proteins, sug- 
gesting that CD28 interacts with protein tyrosine kinase(s) 
in these primed T cells (14). The kinase(s) involved has not 
been identified, and the identities of the tyrosine-phosphory- 
lated proteins are not known. Extensive crosslinking of anti- 
CD28 mAb elicits polyphosphoinositide turnover and increases 
in the concentration of cytoplasmic-free calcium, but these 
signals are not detected after stimulation with bivalent anti- 
CD28 mAb (15). Because bivalent anti-CD28  mAbs elicit 
many CD28-induced cellular responses, it is unlikely that poly- 
phosphoinositide  turnover  plays  a  major  role  in  CD28- 
mediated signaling. 
In this report, we establish that stimulation of CD28, ei- 
ther with B7 or with an anti-CD28 mAb, triggers an associ- 
ation between CD28 and phosphatidylinositol 3-kinase (PI3- 
K). This association is likely to be of importance for CD28 
signaling, in view of the mounting evidence that interactions 
with H3-K play a critical role in signal transduction by a 
number of growth factor receptors. 
Materials and Methods 
Antibodies.  mAbs 9.3 (IgG2a; anti-CD28, human), 19.4 (IgG1; 
anti-CD3e,  human),  and  C305 (IgM;  anti-TCR, Jurkat) were 
generous gifts of Dr. Jeffrey Ledbetter (Bristol-Meyers  Squibb Re- 
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of California, San Francisco). OKTll (IgG1; anti-CD2,  human) 
was derived from a hybridoma line obtained through the Amer- 
ican Type  Culture Collection. Rabbit antiserum to p85 was pur- 
chased from Upstate  Biotechnology, Inc. (Lake Placid, NY). 
Cell Culture and Stimulation Conditions.  P815  cells (mouse masto- 
cytoma) transfected with human B7 (B7/P815.6) and the parent 
P815 line were a generous gift of Dr. Lewis Lanier (DNAX Re- 
search Institute for Molecular and Cellular Biology, Palo Alto, CA) 
(16). P815 cells were grown in complete RPMI 1640 medium, and 
the B7/P815.6  line was cultured  in complete RPMI  1640 sup- 
plemented with I mg/ml G418. Jurkat cells were stimulated with 
mAb (10/zg/ml) in I ml of  complete B.PMI 1640 medium at 37~ 
for 2 min, were pelleted by centrifugation,  and then were lysed 
in 0.9 ml of buffer composed of 1% Triton X-100, 50 mM Hepes 
(pH 7.5),  150 mM NaC1, 10% glycerol, 1.5 nM MgClz, 1 mM 
EGTA, 100 mM NaF, 10 mM NaPPi, 1 mM Na4VO3, aprotinin 
(10/~g/ml), leupeptin (10/zg/ml),  and 1 mM PMSF. Stimulation 
of  Jurkat cells with P815 or B7/P815.6 cells was carried out at a 
1:2 ratio in 1 ml of complete RPMI 1640 at 37~  After a 5-min 
incubation,  the cells were pelleted by centrifugation  and allowed 
to incubate for an additional 2 min before aspiration of the medium 
and lysis in the buffer described above. 
Immunoprecipitations and Immunoblotting.  Cell lysates were clari- 
fied by centrifugation at 14,000g for 15 min at 4~  For precipita- 
tions with mAbs 9.3 and  19.4, 10 #g of Ab were bound to 30 
/xl of goat anti-mouse Ig-coupled Sepharose 4B (Cappel, West 
Chester, PA). For immunoprecipitation  of p85, 5 #1 of antiserum 
were preincubated with 30/~1 of protein A-coupled Sepharose 4B 
(Sigma Chemical Co., St. Louis, MO). Immunoprecipitates were 
washed three times in buffer (Tris-buffered saline [TBS]; 20 mM 
Hepes, pH 7.5, 150 mM NaC1, 0.1% Triton X-100, 10% glycerol, 
1 mM Ya4VO3) and resuspended in 35/11 Laemmli sample buffer. 
Solubilized immunoprecipitates were heated to 95~  for 2 min and 
resolved  by SDS-PAGE, under reducing conditions. Gels  were sub- 
sequently transferred to polyvinylidene  difluoride membranes (Mil- 
lipore Corp.,  Bedford, MA) using a semi-dry transfer apparatus 
(Semi-Phor; Hoefer Scientific Instruments,  San Francisco, CA). 
Membranes were blocked overnight with 5% milk in TBS (10 mM 
Tris, pH 8.0, and 150 mM NaC1). Incubation with p85 antiserum 
was at a dilution of 1:5,000 in TBS, 0.05% Tween 20 (TBST) for 
90 min at room temperature. Membranes were washed four times 
in TBST, and then incubated with alkaline phosphatase-conjugated 
goat anti-rabbit Ig at a concentration  of I/xg/ml in TBST for 
1 h at room temperature. Detection by visualization was carried 
out after four 5-10 min washes ofimmunoblots in TBST. 5-Bromo- 
4-chloro-3-indoylphosphate p-toluidine salt and nitroblue tetrazo- 
lium chloride substrates (GIBCO BRL, Gaithersburg, MD) were 
used according to the manufacturer's instructions. 
Assay  for PI3-K Activity.  Immunoprecipitations were conducted 
as above and washed sequentially as follows: three times in  1% 
Triton X-100, PBS; twice in 0.5 M LiC1, 100 mM Tris, pH 7.6; 
twice in 100 mM Tris, pH 7.6, 100 mM NaC1, 1 mM EDTA; and 
twice in 20 mM Hepes, pH 7.5, 50 mM NaC1, 5 mM EDTA, 30 
mM NaPPi, 200 #M Na4VO3, 0.03% Triton X-100, 1 mM PMSF. 
Immunoprecipitates were then resuspended in 30 #1 of a 1.67X 
reaction mixture composed of the following: 20/~1 of 1 M Tris, 
pH 7.6, 75/zl of I M NaC1, 10 #1 of i M MgC12, 493 #1 of fresh 
200 #M adenosine stock, and 2 #1 of fresh 10 mM ATP stock. 
10/zCi of 3~-[32P]ATP  (5,000 Ci/mM; Amersham Corp., Arling- 
ton Heights, IL) in 10/~1  of volume, and 10/~g PI 4,5-bisphosphate 
(PIP2; Sigma Chemical Co.) in 10/zl of 20 mM Hepes, pH 7.5, 
were added to each reaction mixture. PIP2 was prepared by drying 
a chloroform stock under vacuum and adding the appropriate  volume 
of Hepes buffer (see above). The PIP2, Hepes buffer mixture was 
placed in a bath sonicator for 10 min before use. Immunoprecipi- 
tates were then incubated with PIPs and y-[3~p]ATP for 10 rain 
on a rotator at room temperature. Kinase reactions were stopped 
by addition of 100/~1 1 N HC1, and PI lipids were extracted into 
300/zl of chloroform/methanol  (1:1). An additional aqueous ex- 
traction was performed with 100 #1 of distilled water, and the re- 
maining organic phase was dried under vacuum. Samples were 
resuspended in 20 #1 of chloroform/methanol  (1:1) and resolved 
by thin layer chromatography as described (17). Radiolabeled PI 
3,4,5-trisphosphate (PIP3) was detected by autoradiography with 
plates exposed overnight at  - 70~  to Kodak XOMAT AR5 film, 
backed by an intensifying screen. Inositol phospholipid standards 
were visualized by iodine vapor. 
Peptide Inhibition Studies.  Oligopeptides corresponding to all po- 
tential phosphotyrosines on the human CD28 cytoplasmic  tail were 
synthesized as described (18) with the following sequences (Y* indi- 
cates phosphotyrosine,  and  residue number  is  in  parentheses): 
LHSDY*  (173)MNMTPRRPG,  PTRKHY*  (188)QPYAPPRD, 
KHYQPY*(191)APPRDFAA, and QPYAPPRDFAAY* (200)RS. 
The nonphosphorylated oligopeptide  LHSDY(173)MNMTPRRPG 
also was synthesized.  Oligopeptides  were dissolved  in PBS and stored 
in frozen aliquots at  -70~ 
Results 
Stimulation of CD28 with Either a CD28 mAb or B7 Induces 
an Association between CD28 and the p85 subunit of  PI3-K.  PI3-K 
consists of a 110-kD catalytic subunit (pl10) and an 85-kD 
regulatory subunit (p85) (19).  The latter mediates interac- 
tions between PI3-K and a number of tyrosine-phosphorylated 
growth factor receptors and other molecules (19). To deter- 
mine whether PI3-K associates  with  CD28,  we analyzed 
CD28 immunoprecipitates from Jurkat T cells for the pres- 
ence of PI3-K p85 by immunoblotting and for the presence 
of PI3-K activity by an in vitro kinase assay. Jurkat cells rep- 
resent a well-studied model for T cell activation and express 
functional CD28  molecules (12). 
PI3-K p85 is not detected in CD28 immunoprecipitates 
from unstimulated Jurkat cells or from cells exposed to OKTll, 
a mAb to CD2 (Fig.  1 A, lanes I  and 2). In contrast, when 
Jurkat cells are stimulated with a CD28 mAb (9.3) before 
lysis, p85 coimmunoprecipitates with CD28 (Fig.  1 A, lane 
3). A time course study demonstrates that exposure of  Jurkat 
cells to anti-CD28 for 30 s is sufficient to elicit the associa- 
tion between CD28 and p85 and that this association per- 
sists for at least 40 min after the addition of the mAb (Fig. 2). 
To determine whether the natural ligand for CD28 also 
induces an association between CD28 and PI3-K p85,  we 
incubated Jurkat cells with P815 cells that express B7 after 
gene transfer (B7/P815.6 cells)  (16).  Exposure to the B7/ 
P815.6 cells, but not the untransfected P815 control, leads 
to the coimmunoprecipitation of p85 with CD28  (Fig.  1, 
A and B). This coimmunoprecipitation requires exposure of 
intact Jurkat cells to intact B7/P815.6 cells and is not ob- 
served when lysates of the two cell types are simply mixed 
(data not shown).  In contrast to the results obtained with 
CD28,  p85 is not detected in immunoprecipitates of CD3 
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Jurkat cells stimulated either with anti-CD28 mAb or B7-expressing P815 
cells. (A) Jurkat cells (2  ￿  107)  were lysed after incubation in medium 
alone (lane 1), after the addition of mAbs OKTll (anti-CD2; lane 2) or 
9.3 (anti-CD28; lane 3), or after incubation with either P815 cells (lane 
4) or B7/P815.6  cells (lane 5).  CD28 was immunoprecipitated from ly- 
sates, and the immunoprecipitates were then analyzed for the presence of 
PI3-K p85 by immunoblotting with a rabbit antiserum to p85.  (Lane 6) 
PI3-K p85, directly immunoprecipitated with the p85 antiserum from a 
lysate of 5  x  106 Jurkat cells. PI3-K p85 migrates as a doublet, probably 
due to differential migration of the two isoforms of p85. Because the PI3-K 
p85 antiserum does not deplete all cellular p85 (data not shown), compar- 
ison of the intensity of the p85 bands in this experiment does not reflect 
accurately the stoichiometry of the association between p85 and CD28. 
(/3) Lysates from 107 Jurkat cells that had been stimulated with B7/P815.6 
cells were subjected  to immunoprecipitation with either mAh 9.3 (anti- 
CD28; lane 2), OKTll (anti-CD2; lane 3), or 19.4 (anti-CD3e; lane 4). 
Immunoblot analysis with the p85  antiserum reveals PI3-K p85  in the 
CD28 immunoprecipitates but not the CD3 or CD2 immunoprecipitates. 
p85 is not detected in CD28 immunoprecipitates from Jurkat cells exposed 
to control P815 cells (lane  I). 
Figure  3.  PI3-kinase activity associates with CD28.  (A) Before lysis, 
Jurkat cells were either incubated in either medium alone (O) or coin- 
cubated with P815 cells or B7/P815.6  cells as indicated. Immunoprecipi- 
tates (PlaN) using goat anti-mouse Ig (G~MIg; lane 1), an antiserum 
to PI3-K p85 (~p85; lane 2), or 9.3 (anti-CD28; lanes 3-6) were analyzed 
for the presence of PI3-K enzymatic activity using qc-[32P]ATP and PIP2 
as substrate. The reaction products were resolved by thin layer chromatog- 
raphy and revealed by autoradiography. PI3-K, which generates [3zP]PIP3 
in this assay, is present  in PI-3K p85 immunoprecipitates and in CD28 
immunoprecipitates from Jurkat cells exposed to B7/P815.6  cells. Under 
these conditions, stimulation with B7/P815.6  cells does not induce a de- 
tectable  change in PI3-K activity in p85  immunoprecipitates (data not 
shown). In the experiments shown in lanes 5 and 6, CD28 immunoprecipi- 
tations were performed in the presence of 50/zM of tyrosine-phosphorylated 
(PY173) or nonphosphorylated (Y173) oligopeptides corresponding to Tyr 
173 of the CD28 cytoplasmic domain. (Lane 2) p85 immunoprecipitated 
from 5  x  106 Jurkat cells; all other experiments represent immunoprecipi- 
tares from 2  x  107Jurkat  cells. (Right) The origin and position of phos- 
phatidylinositol (P/), phosphatidylinositol 4-monophsophate (PIP), and 
PIP2 standards. (B) Lysates from 107 Jurkat cells that had been stimulated 
with 2  x  107 B7/P815.6  cells were subjected to immunoprecipitates  with 
mAb 9.3 (anti-CD28), 19.4 (anti-CD3e) or OKTll (anti-CD2). PI3-K 
enzymatic assays were performed on the resulting immunoprecipitates. 
PI3-K activity is present only in the CD28  immunoprecipitate. 
Figure  2.  Time course of the association of PI3-K p85 with CD28 after 
the  addition of anti-CD28  mAb  to Jurkat  cells. Jurkat  cells  (107 per 
sample) were stimulated with the anti-CD28 mAb 9.3 for the indicated 
time periods before lysis. CD28 immunoprecipitates from these lysates were 
analyzed  for PI3-K p85 by immunoblotting. 
and CD2  from Jurkat cells exposed to B7/P815.6  cells (Fig. 
1  B). 
PI3-K Enzymatic Activity Associates with CD28.  To assay 
for PI3-K enzymatic activity in association with CD28,  we 
performed  kinase  reactions  on  CD28  immunoprecipitates, 
using PIP2 as a  substrate.  The action of PI3-K on PIP2 yields 
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chromatography  (Fig.  3 A, lane 2).  Of the known inositol 
lipid kinases, only PI3-K can phosphorylate PIP2.  In accord 
with the p85 immunoblot studies, PI3-K activity is present 
in CD28 immunoprecipitates from Jurkat cells that have been 
exposed to B7/P815.6 cells but not from Jurkat cells incubated 
with control P815 cells (Fig. 3 A, lanes 3 and 4). Also con- 
sistent with the p85 studies, PI3-K activity is not found in 
immunoprecipitates of CD3 and CD2 from the B7/P815.6- 
exposed Jurkat cells (Fig. 3 B, lanes 2 and 3), indicating that 
PI-3K selectively coimmunoprecipitates with CD28. These 
results suggest that  CD28 stimulation  leads to the binding 
of a p85/p110 PI3-K heterodimer  to CD28.  Alternatively, 
an inactive p110 subunit  may be associated with  CD28 in 
the resting  state and may become catalytically active upon 
CD28  stimulation  and  the binding  of p85. 
The Association between  CD28 and PI3-K  p85 Is Independent 
of TCR Signals.  Because CD28-derived signals augment lym- 
phokine production byJurkat cells that have been stimulated 
by TCR mAb and PMA, we investigated the relationships 
between the TCR  signaling,  PMA  treatment,  and  the as- 
sociation of CD28 with PI3-K (2). CD28 ligation does not 
require TCR stimulation  or the addition of PMA in order 
to trigger the association with PI3-K (Figs.  1-3). Moreover, 
the addition of PMA,  a TCR mAb, or the combination of 
a TCR mAb and PMA,  does not induce PI3-K p85 to as- 
sociate with  CD28  (Fig.  4).  When Jurkat  cells  have been 
treated with anti-TCR and PMA, perturbation of CD28 still 
induces  the association  with  p85  (Fig.  4).  The  association 
of CD28 with PI3-K p85, therefore, appears to be indepen- 
dent  of TCR-derived  signals  and  of PMA. 
A  Tyrosine-phosphorylated  Peptide Corresponding  to the Sequence 
Surrounding Tyr 173 of the CD28 Cytoplasmic Domain Inhibits 
the Interaction between  CD28 and PI3-K.  PI3-K p85 contains 
two src homology 2 (SH2) domains that allow p85 to bind 
with high affinity to tyrosine-phosphorylated sequences con- 
taining  YMXM or YXXM motifs (where X  is any amino 
acid) (18, 20). The CD28 cytoplasmic domain has four tyro- 
Figure 5.  Effect of tyrosine-phosphorylated oligopeptides from the 
CD28 cytoplasmic  domain on the coimmunoprecipitation of p85 with 
CD28. CD28 immunoprecipitates from 107 Jurkat cells that had been 
exposed  to either P815 cells  or B7/P815.6  cells  were  analyzed  for the pres- 
ence of PI3-K p85 by immunoblotting. Where indicated, tyrosine-phos- 
phorylated oligopeptides (PY) corresponding to each tyrosine  residue on 
the CD28 cytoplasmic  tail were added in a final concentration of 50 #M 
to each lysate  before  immunoprecipitation. The oligopeptide  corresponding 
to Tyr 173 was also added in its nonphosphorylated form (Y173). 
sine residues, one of which (Tyr 173) is contained in the se- 
quence YMNM (21).  To examine the possibility that phos- 
phorylation of CD28 tyrosine residues forms a binding site 
for PI3-K p85, we tested tyrosine-phosphorylated oligopep- 
tides corresponding to each of the four cytoplasmic tyrosines 
and their surrounding sequences for the ability to inhibit the 
coprecipitation of PI3-K with CD28. When added to lysates 
of  Jurkat cells that had been stimulated with B7/P815.6 cells, 
the phosphorylated oligopeptide corresponding  to Tyr 173 
completely prevents the coimmunoprecipitation of p85 with 
CD28 (Fig.  5). This inhibition  requires phosphorylation;  a 
nonphosphorylated version of the same oligopeptide has no 
effect (Fig.  5). Inhibition by the Tyr 173 oligopeptide, more- 
over, is specific. Phosphorylated oligopeptides corresponding 
to the other tyrosine residues of CD28 do not affect the as- 
sociation of p85 with CD28 (Fig.  5). Addition of the phos- 
phorylated Tyr 173 oligopeptide to the lysate also prevents 
the coimmunoprecipitation of PI3-K enzymatic activity with 
CD28  (Fig.  3,  lanes  5  and 6). 
Figure 4.  Effect  of PMA and TCR stimulation on the association of 
p85 with CD28. CD28 immunoprecipitates from 1.5  x  107 Jurkat cells 
were analyzed for the presence of p85 by immunoblotting. Jurkat cells 
were first cultured for 6 h in either medium alone (lanes t, 3, 5, and 7) 
or medium supplemented with 5 ng/ml of PMA (lanes 2, 4, 6, and 8). 
Cells were  lysed  without additional stimulation (O), after stimulation for 
2 min with the TCR mAb C305 (10/~g/ml), or after  exposure  to B7/P815.6. 
Discussion 
In this report we demonstrate that stimulation of CD28, 
either by its natural  ligand,  B7, or by a mAb,  triggers  an 
association between CD28 and PI3-K in Jurkat T cells. The 
association occurs within 30 s of mAb-mediated perturba- 
tion of CD28 and persists for more than 40 min. In contrast 
to detectable CD28-mediated tyrosine phosphorylations, the 
association does not require pretreatment with a TCR mAb 
or with  PMA (14). 
Tyrosine phosphorylation of certain growth factor receptors 
creates high  affinity binding  sites  for the SH2 domains  of 
PI3-K p85 (18,  20). A  similar phosphorylation  mechanism 
mediates the interaction between PI3-K and CD19, a B cell 
accessory molecule which can potentiate  cellular responses 
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gest, but do not firmly establish,  that  phosphorylation  of 
Tyr 173 of the CD28 cytoplasmic domain mediates the inter- 
action of CD28 with PI3-K. Tyr 173 is just COOH-terminal 
to a negatively charged residue (aspartic  acid), consistent with 
the possibility that it is a phosphorylation site (21). Moreover, 
Tyr 173 is contained within  the sequence YMNM,  which 
is also found in the PI3-K binding site of the platelet-derived 
growth factor (PDGF) receptor (18).  When tyrosine phos- 
phorylated, peptides containing this sequence bind the SH2 
domains of PI3-K p85 with high affinity (20). We find that 
a tyrosine-phosphorylated oligopeptide corresponding to the 
sequence surrounding Tyr 173 inhibits the coimmunoprecipi- 
tation of PI3-K with CD28.  The simplest explanation  for 
this result is that  the Tyr 173 oligopeptide competes with 
CD28  for binding  to  the p85  SH2 domains,  thereby dis- 
sociating PI3-K from CD28. One model for the interaction 
of PI3-K with CD28, therefore, is that perturbation of CD28 
induces tyrosine phosphorylation of Tyr 173, which in turn 
binds the p85 SH2 domains, creating a stable association be- 
tween CD28 and PI3-K. Our attempts to demonstrate directly 
that CD28 is tyrosine phosphorylated have generated equivocal 
results (data not shown). This difficulty may simply reflect 
a low stiochiometry of phosphorylation and the insensitivity 
of our detection methods. It remains possible, however, that 
CD28 interacts with PI3-K through a mechanism that does 
not  involve tyrosine phosphorylation. 
Tyrosine-phosphorylated peptides that bind the p85 SH2 
domains stimulate PI3-K enzymatic activity, suggesting that 
the interactions  of p85 with tyrosine-phosphorylation receptors 
may activate PI3-K allosterically (23, 24). How activated PI3-K 
influences  cellular  responses  is  uncertain.  PIP3  and  other 
D-3-phosphorylated  inositol lipids  selectively activate pro- 
tein kinase C~" in vitro, but it is not known whether these 
products of PI3-K regulate the activity of this serine/threo- 
nine kinase in vivo (25). The apparent yeast homolog of the 
PI3-K catalytic subunit controls vacuolar sorting, raising the 
possibility, for which there is as yet no firm evidence, that 
PI3-K also may regulate protein trafficking and targeting to 
specific  subcellular compartments  (26). 
Mutants of the PDGF receptor that fail to bind PI3-K have 
impaired abilities to transduce mitogenic signals (27, 28). These 
and similar observations underscore the potential importance 
of receptor interactions with PI3-K and indicate that an as  o 
sociation with PI3-K is likely to play a role in CD28-mediated 
signaling triggered by binding B7. Of interest, CTLA-4, an- 
other B7 counter receptor expressed by T cells, contains the 
sequence YVKM and, therefore, also may bind PI3-K (29). 
The known components of the TCR,  on the other hand, 
lack YMNM and YXXM motifs, and are unlikely to bind 
PI3-K p85 with high affinity.  Receptors that interact with 
PI3-K, therefore, may deliver a stimulus that differs qualita- 
tively from the TCR signal. 
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